The Merck-Revolution Split: Valuation Discipline and Biotech Fallout

Merck has ended acquisition talks with Revolution Medicines over valuation disagreements. This event is causing a reset in biotech deal premiums and impacting speculation for future M&A targets in the oncology space.

Listen